{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:27Z","timestamp":1759335267388,"version":"3.44.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jcjo.2019.11.004","type":"journal-article","created":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T03:00:38Z","timestamp":1577847638000},"page":"245-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Guidelines for vismodegib in the management of periocular basal cell carcinoma"],"prefix":"10.1016","volume":"55","author":[{"given":"Ahsen","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan D.","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian T.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edsel","family":"Ing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Arthurs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmeet S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Kratky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navdeep","family":"Nijhawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Oestreicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aftab","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2019.11.004_bib0001","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0161-6420(99)90161-6","article-title":"Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota","volume":"106","author":"Cook","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0002","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ophtha.2003.11.004","article-title":"The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up","volume":"111","author":"Malhotra","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0003","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/SAP.0b013e3181953a5e","article-title":"Clinical outcome of surgical treatment for periorbital basal cell carcinoma","volume":"63","author":"Kakudo","year":"2009","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0004","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00002341-200211000-00008","article-title":"Management of periocular basal cell carcinoma with modified en face frozen section controlled excision","volume":"18","author":"Wong","year":"2002","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ajo.2006.03.055","article-title":"Management of periocular basal and squamous cell carcinoma: a series of 485 cases","volume":"142","author":"Nemet","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0006","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/IOP.0b013e3182a74f21","article-title":"Eyelid margin basal cell carcinoma managed with full-thickness en-face frozen section histopathology","volume":"30","author":"Gill","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0007","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0008","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","article-title":"Vismodegib for periocular and orbital basal cell carcinoma","volume":"131","author":"Gill","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0009","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IOP.0b013e3182831bf3","article-title":"Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma","volume":"29","author":"Yin","year":"2013","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0010","doi-asserted-by":"crossref","first-page":"432","DOI":"10.12998\/wjcc.v2.i9.432","article-title":"Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas","volume":"2","author":"Yin","year":"2014","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0011","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaophthalmol.2013.4430","article-title":"Vismodegib for eye-threatening orbital basal cell carcinoma","volume":"131","author":"Kahana","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0012","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaophthalmol.2013.4430","article-title":"Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma","volume":"131","author":"Kahana","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0013","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1055\/s-2007-963633","article-title":"[The Montreal definition and classification of gastroesophageal reflux disease: a global, evidence-based consensus paper] [article in German]","volume":"45","author":"Vakil","year":"2007","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0014","unstructured":"Pan-Canadian Oncology Drug Review Final Economic Guidance Report\u2014Vismodegib (Erivedge) for Basal Cell Carcinoma, 2013. https:\/\/cadth.ca\/pcodr"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0015","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OTT.S130371","article-title":"Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment","volume":"10","author":"Shi","year":"2017","journal-title":"Oncol Targets Ther"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0016","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","article-title":"Efficacy of vismodegib (Erivedge) for basal cell carcinoma involving the orbit and periocular area","volume":"31","author":"Demirci","year":"2015","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0017","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/SCS.0000000000003242","article-title":"Periocular basal cell carcinoma predictors for recurrence and infiltration of the orbit","volume":"28","author":"Furdova","year":"2017","journal-title":"J Craniofac Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0018","unstructured":"BC Cancer Agency Cancer Drug Manual, 2015. http:\/\/www.bccancer.bc.ca\/health-professionals\/clinical-resources\/cancer-drug-manual"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0019","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1600-0625.2011.01275.x","article-title":"Epidemiologic risk factors of basal cell carcinoma development and age at onset in a Southern European population from Greece","volume":"20","author":"Dessinioti","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0020","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of non-melanoma skin cancer","volume":"166","author":"Lomas","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0021","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/ajt.14382","article-title":"Skin cancers in organ transplant recipients","volume":"17","author":"Mittal","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0022","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-4632.2006.02673.x","article-title":"Current modalities and new advances in the treatment of basal cell carcinoma","volume":"45","author":"Ceilley","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0023","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/S0161-6420(01)00796-5","article-title":"Treatment options and future prospects for the management of eyelid malignancies","volume":"108","author":"Cook","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0024","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archopht.1986.01050180135046","article-title":"Micrographic surgery for the microscopically controlled excision of eyelid cancers","volume":"104","author":"Mohs","year":"1986","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0025","first-page":"6","article-title":"Conventional frozen sections in periocular basal-cell carcinoma","volume":"23","author":"Glatt","year":"1992","journal-title":"Ophthalmic Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0026","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/bjo.2004.058834","article-title":"Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome","volume":"89","author":"Hamada","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0027","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1524-4725.1996.tb00316.x","article-title":"Basal cell carcinoma: identification and treatment of the high risk patient","volume":"22","author":"Randle","year":"1996","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0028","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2217\/fon.15.190","article-title":"Management of peri-orbital basal cell carcinoma with orbital invasion","volume":"11","author":"Sun","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0029","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.IOP.0000066699.53489.88","article-title":"Orbital exenteration: results of an individualized approach","volume":"19","author":"Goldberg","year":"2003","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0030","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0031","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome","volume":"366","author":"Tang","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0032","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Basset-S\u00e9guin","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0033","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2017.10.006","article-title":"Guidelines of care for the management of basal cell carcinoma","volume":"78","author":"Kim","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0034","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/bjophthalmol-2018-312277","article-title":"Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma","volume":"103","author":"Sagiv","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/IOP.0000000000001166","article-title":"Neoadjuvant vismodegib and Mohs micrographic surgery for locally advanced periocular basal cell carcinoma","volume":"35","author":"Gonz\u00e1lez","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0036","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IOP.0000000000001251","article-title":"Impact of Food and Drug Administration approval of vismodegib on prevalence of orbital exenteration as a necessary surgical treatment for locally advanced periocular basal cell carcinoma","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2019.11.004_bib0037","unstructured":"Pharmaceutical Benefits Scheme (PBS). Vismodegib: Capsule 150 mg; Erivedge.www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2016-11\/vismodegib-psd-november-2016."},{"key":"10.1016\/j.jcjo.2019.11.004_bib0038","unstructured":"National Institute for Health and Care Excellence. Vismodegib for treating basal cell carcinoma. www.nice.org.uk\/guidance\/ta489\/resources."}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418219309895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418219309895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:09:54Z","timestamp":1757794194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418219309895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0008418219309895"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2019.11.004","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines for vismodegib in the management of periocular basal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2019.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}